Informações:
Falhas:
ID
22148
Descrição
ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00312377
Link
https://clinicaltrials.gov/show/NCT00312377
Palavras-chave
Versões (1)
- 21/05/2017 21/05/2017 -
Transferido a
21 de maio de 2017
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Non-small Cell Lung Cancer NCT00312377
Eligibility Non-small Cell Lung Cancer NCT00312377
- StudyEvent: Eligibility
Similar models
Eligibility Non-small Cell Lung Cancer NCT00312377
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
lung cancer
Item
lung cancer patients who answer true to the following statements are eligible to join this clinical study.
boolean
C0242379 (UMLS CUI [1])
locally advanced or metastatic nsclc
Item
i have a confirmed diagnosis of locally advanced or metastatic non small cell lung cancer (stage iiib - iv)
boolean
C0007131 (UMLS CUI [1,1])
C0679246 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,3])
C0679246 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,3])
nsclc first line therapy
Item
i have had 1st line anti-cancer therapy. previous treatment with avastin (bevacizumab) in first line nsclc is allowed.
boolean
C0007131 (UMLS CUI [1,1])
C1708063 (UMLS CUI [1,2])
C1708063 (UMLS CUI [1,2])
lung cancer
Item
lung cancer patients who answer true to the following are not eligible to join this clinical study.
boolean
C0242379 (UMLS CUI [1])
nsclc
Item
i do not have non small cell lung cancer (nsclc)
boolean
C0007131 (UMLS CUI [1])
docetaxel
Item
i have received treatment with docetaxel (taxotere). prior treatment with paclitaxel is acceptable.
boolean
C0246415 (UMLS CUI [1])
nsclc second line therapy
Item
i have received 2nd line anti-cancer therapy (for example, patients with previous 2nd line non small cell lung cancer (nsclc) treatment with tarceva (erlotinib, osi-744), alimta (pemetrexed) are not eligible)
boolean
C0007131 (UMLS CUI [1,1])
C1710038 (UMLS CUI [1,2])
C1710038 (UMLS CUI [1,2])
vegfr tyrosine kinase inhibitors
Item
i have been treated with vegfr-tyrosine kinase inhibitors (tkis) (sunitinib, sorafenib, other vegf tkis). previous treatment with avastin (bevacizumab) in 1st line non small cell lung cancer is permitted.
boolean
C2985521 (UMLS CUI [1])
arrhythmias
Item
i have a history of uncontrolled irregular heartbeat
boolean
C0003811 (UMLS CUI [1])
hypertension
Item
i have a history of high blood pressure which has not been controlled with medication if you are unsure of the meaning of the inclusion and exclusion criteria above, please contact the call center number for help.
boolean
C0020538 (UMLS CUI [1])